Revelation Biosciences, Inc.
REVBW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $9.99K in total; no superinvestor holds it.
Other share classesREVB
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 13
- 13F valueReported value at the end of Q2 2026
- $9.99K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding REVBW, Q2 2026
No superinvestor reported holding REVBW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Revelation Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 12, 2023 (view filing) | Dec 8 | 4 days | Tidmarsh George FDirector | SSale | −27.8K | $0.52 | −$14.4K | −100.0%0 after | |
| Oct 18, 2023 (view filing) | Oct 16 | 2 days | Tidmarsh George FDirector | SSale | −1.84K | $0.65 | −$1.20K | −6.2%27.8K after | |
| Oct 17, 2023 (view filing) | Oct 16 | 1 day | Tidmarsh George FDirector | SSale | −11.0K | $0.66 | −$7.23K | −20.7%42.1K after | |
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Tidmarsh George FDirector | SSale | −1.43K | $0.69 | −$986.01 | −3.3%42.1K after | |
| Sep 18, 2023 (view filing) | Sep 14-18 | 4 days | Tidmarsh George FDirector | SSale | −25.5K | $0.741 | −$18.9K | −39.3%39.3K after | 3 lots |
| Apr 19, 2023 (view filing) | Apr 17-18 | 2 days | Tidmarsh George FDirector | PPurchase | +51.5K | $1.16 | +$59.7K | +385.8%64.8K after | 2 lots |
| Feb 28, 2022 (view filing) | Feb 25 | 3 days | Tidmarsh George FDirector, 10% Owner | PPurchase | +20.0K | $1.60 | +$32.0K | +4.5%467.2K after | |
| Feb 10, 2022 (view filing) | Feb 8-9 | 2 days | Tidmarsh George FDirector, 10% Owner | PPurchase | +31.0K | $2.55 | +$79.0K | +7.4%447.2K after | 2 lots |
| Feb 9, 2022 (view filing) | Feb 4-7 | 5 days | Tidmarsh George FDirector, 10% Owner | PPurchase | +50.0K | $2.56 | +$128.1K | +3.4%1.52M after | Amended2 lots |
| Feb 9, 2022 (view filing) | Feb 4 | 5 days | Tidmarsh George FDirector, 10% Owner | PPurchase | +2.00K | $2.45 | +$4.90K | +0.5%416.2K after | Amended |
Top 10 13F holders, Q2 2026
The largest institutional positions in Revelation Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Linden Advisors LP | 337,752 | $2.40K | 0.00% | −358−0.1% | Reduced |
| Clear Street Group Inc. | 246,934 | $1.95K | 0.00% | −600−0.2% | Reduced |
| Pine Valley Investments Ltd Liability Co | 236,857 | $1.87K | 0.00% | −8,572−3.5% | Reduced |
| T3 Companies, LLC | 198,090 | $1.56K | 0.00% | 00.0% | Unchanged |
| Toronto Dominion Bank | 99,050 | $792 | 0.00% | −500−0.5% | Reduced |
| Wolverine Asset Management LLC | 54,752 | $433 | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 50,000 | $395 | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 42,266 | $262 | 0.00% | +42,266 | New |
| Soltis Investment Advisors LLC | 22,500 | $178 | 0.00% | −25,000−52.6% | Reduced |
| Citadel Advisors LLC | 18,716 | $116 | 0.00% | −13,684−42.2% | Reduced |